Synairgen (LON:SNG) Stock Price Down 2.9% – What’s Next?

Synairgen plc (LON:SNG) traded down 2.9% during mid-day trading on Monday . The company traded as low as GBX 0.80 ($0.01) and last traded at GBX 0.83 ($0.01). 160,793 shares traded hands during mid-day trading, a decline of 90% from the average session volume of 1,578,296 shares. The stock had previously closed at GBX 0.85 ($0.01).

Synairgen Stock Down 2.6 %

The stock’s fifty day moving average price is GBX 1.54 and its 200-day moving average price is GBX 2.93. The company has a market capitalization of £9.04 million, a price-to-earnings ratio of -0.56 and a beta of -2.23.

About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).